UPSTATE CAROLINA COMMUNITY CLINICAL ONCOLOGY PROGRAM

卡罗莱纳州北部社区临床肿瘤学计划

• 批准号: 2712568
• 负责人: James D Bearden
• 金额: $ 44.88万
• 依托单位: SPARTANBURG REGIONAL MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1983
• 资助国家: 美国
• 起止时间: 1983-09-01 至 2001-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2712568
• 关键词: aspirin; behavioral /social science research tag; breast neoplasms; cancer prevention; cancer rehabilitation /care; chemoprevention; clinical research; colorectal neoplasms; community health services; cooperative study; dietary calcium; early diagnosis; head /neck neoplasm; health science research analysis /evaluation; human morbidity; human mortality; human subject; human therapy evaluation; information dissemination; longitudinal human study; lung neoplasms; neoplasm /cancer diagnosis; neoplasm /cancer education; neoplasm /cancer nutrition therapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer therapy; nutrition related tag; patient care management; prostate neoplasms; quality of life; therapy compliance

Building on 12 years of experience as a CCOP, the Spartanburg Community Clinical Oncology Program (SCCOP) seeks the opportunity to continue to meet our community's need for innovative and relevant studies of promising therapeutic modalities and cancer control research through the Year 2001. The SCCOP provides access to national cooperative clinical trials to nearly a half million people in 6 counties: 3 in South Carolina and 3 in North Carolina. South Carolina is 21st in population density and ranks 14th in the percent who are medically underserved. The service area has a 20% minority base. The regional registry reports over 1,100 new cancer patients per year, an increase of over 158% since 1982. Against this rural background, we developed a three hospital consortium for the conduct of community clinical trials. Unique capacities are demonstrated by the minority accrual over 17% and by the underserved accrual of 84 entries in the last seven years. The SCCOP brings together the strength and resources of a group of multidisciplinary investigators who collaborate in the conduct of studies from SWOG, NSABP, RTOG, and MDACC. The 46 investigators include a single, small, stable, and highly productive practice of 3 hematologists/oncologists along with 41 colleagues in pathology, radiation therapy, surgery, ENT, urology, gastroenterology, as well as internal medicine. The group nearly tripled in size since the early 1990's and together has contributed over 1700 entries to clinical trials since 1983, the start of the CCOP. Over the next five years, the overall aim is to reduce cancer incidence, morbidity, and mortality by accelerating the transfer of newly developed cancer prevention, early detection, treatment, patient management, rehabilitation, and continuing care technology to widespread community application. By careful design, the program will focus over 60% of our resources on cancer control research. These complementary objectives of both treatment and cancer control are a ready match for the patient population and fit within SCCOP interests and capabilities. The immediate goals of the SCCOP are to increase our accrual rate to treatment trials; to maintain wide community participation, including minority groups and underserved populations, in both treatment and cancer control research approved by NCI; and to continue to refine cancer control data management capabilities, including the use of a range of resources to identify potential candidates for cancer control research projects. The continuation of the Breast Cancer Prevention Trial (BCPT), the Prostate Cancer Prevention Trial (PCPT), the Colorectal Prevention Trials, and the upcoming Smoker's Chemoprevention Trial are primary objectives. In summary, the SCCOP track record demonstrates the ability to manage complex clinical research and cancer control activities while producing the highest quality data. The SCCOP has the facilities and well-trained professional personnel to support the full array of studies. The SCCOP staffing pattern, protocol management procedures, patient/participant management approaches, quality control mechanisms, IRS structure and liaison are all in place and functioning to support current and future therapeutic and cancer control activities. Over the next five years, we expect to contribute over 1500 credits to the National Cancer Institute's Community Clinical Oncology Program: over 133 treatment credits and over 183 cancer control credits each year through 2001.

凭借12年的CCOP经验，斯帕坦堡社区 临床肿瘤学计划（SCCOP）寻求继续 满足我们社会对创新和相关研究的需求， 到2001年为止的治疗方式和癌症控制研究。 SCCOP提供国家合作临床试验的机会， 近50万人在6个县：3个在南卡罗来纳州和3个在 北卡罗来纳州。 南卡罗来纳州在人口密度和排名上排名第21位。 在医疗服务不足的人群中排名第14。 服务区有 20%的少数族裔 区域登记处报告了1,100多例新癌症 每年的患者人数，自1982年以来增加了158%以上。 反对这个 农村背景下，我们制定了三个医院联合体的行为 社区临床试验。 独特的能力表现在 少数应计项目超过17%， 过去的七年 SCCOP汇集了一组的力量和资源， 多学科研究者合作开展研究 来自SWOG、NSABP、RTOG和MDACC。 46名调查人员包括一名， 小型、稳定且高效的3 血液学家/肿瘤学家沿着41名病理学、放射学 治疗，外科，耳鼻喉科，泌尿科，胃肠科，以及内部 药 自20世纪90年代初以来，该集团的规模几乎增加了两倍， 自1983年以来，共为临床试验提供了1700多个条目， CCOP的开始。 在未来五年，总体目标是降低癌症发病率， 发病率和死亡率，加速新开发的 癌症预防，早期发现，治疗，病人管理， 康复和持续护理技术，以广泛的社区 应用程序. 通过精心设计，该计划将集中超过60%的我们 癌症控制研究的资源。 这些互补的目标 治疗和癌症控制都适合患者 人口和适合SCCOP的利益和能力。 SCCOP的近期目标是将我们的应计率提高到 治疗试验;保持广泛的社区参与，包括 在治疗和癌症方面， NCI批准的控制研究;并继续完善癌症控制 数据管理能力，包括使用一系列资源， 确定癌症控制研究项目的潜在候选人。 的 乳腺癌预防试验（BCPT）的继续，前列腺 癌症预防试验（PCPT）、结直肠预防试验和 即将到来的吸烟者化学预防试验是主要目标。 总而言之，SCCOP的业绩记录表明， 复杂的临床研究和癌症控制活动， 最高质量的数据。 SCCOP拥有设施和训练有素的 专业人员支持全面的研究。 SCCOP 人员配置模式、方案管理程序、患者/参与者 管理方法、质量控制机制、IRS结构和 联络都已到位，并发挥作用，以支持当前和未来的 治疗和癌症控制活动。 在未来五年内，我们预计将向 国家癌症研究所的社区临床肿瘤学项目：超过133个 治疗信贷和超过183癌症控制信贷，每年通过 2001.